Financials
Financial year 2025
Revenue
€ 197.1 million
▲ 31% vs 2024
Profit
Growing€ 5.7 million
▲ 36% vs 2024
Debts
High€ 66.1 million
▲ 105% vs 2024
S.A. NOVO NORDISK PHARMA N.V. from Dilbeek, company number BE0414695586, closed financial year 2025 with a result of € 5.7 million after tax. For that financial year S.A. NOVO NORDISK PHARMA N.V. recorded revenue of € 197.1 million and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 4.2 million to € 5.7 million. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
What happened at S.A. NOVO NORDISK PHARMA N.V.?
What happened at S.A. NOVO NORDISK PHARMA N.V. in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- David Marcus Svensson stepped down as director. NBB
- Jeppe Theisen stepped down as director. NBB
- Jonas Larsen stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 5.7 million (▲ 36% vs 2024). Source: NBB ↗
- David Marcus Svensson became a director. NBB
- Jeppe Theisen became a director. NBB
- Jonas Larsen became a director. NBB
- New establishment in Dilbeek. KBO
In short
From € 2.3 million profit in 2021 to € 5.7 million profit in 2025.
Paid € 8.4 million in corporate taxes since 2021.
Best year ever: 2025, with € 5.7 million profit.
Paid out € 18.8 million in dividends to the owners in total.
A new publication or filing at S.A. NOVO NORDISK PHARMA N.V.? We notify you, reason included.
Follow S.A. NOVO NORDISK PHARMA N.V.Need more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
David Marcus Svensson
Director
since 2026 · until 2032
Jeppe Theisen
Managing director
since 2026 · until 2032
Jonas Larsen
Director
since 2022 · until 2028
Establishments
Establishment units
Physical locations of this company
Alfons Gossetlaan 32E box 202
1702 Dilbeek
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
MICROSOFT-CORP-MSN-AS-BLOCK - Microsoft Corporation, US
Website info
Features
Security
Details
- Company number
- 0414.695.586
- VAT number
- BE 0414.695.586
- Registered office
- Alfons Gossetlaan 32E bus 202, 1702 Dilbeek
- Names & denominations
- S.A. NOVO NORDISK PHARMA N.V.
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 September 1974
- Peppol
- Active · Active since 30 Mar 2026
- Contact
- novonordisk.be
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten